Recently, the testing center of Shenzhen Rayyan Technology Co., Ltd. (MOTI Magic Flute 2019 Laboratory) has obtained the accreditation from CNAS (China National Accreditation Service for Conformity Assessment), making it one of the few domestic electronic cigarette brand enterprises to have a CNAS-accredited national laboratory.
The acronym CNAS stands for China National Accreditation Service for Conformity Assessment. The recent recognition by CNAS confirms the authoritative recognition of the management level, testing ability, and quality management capabilities of the Lei Yan Testing Center, and signifies the center's comprehensive strength in the electronic atomization industry reaching international standards. This further strengthens Lei Yan's scientific research advantages and lends authoritative endorsement to the quality of its entire product line.
According to a report from NetEase News, CNAS certification has been recognized by both the International Laboratory Accreditation Cooperation (ILAC) and the Asia Pacific Laboratory Accreditation Cooperation (APLAC). This recognition means that testing reports issued by CNAS can be mutually recognized and accepted by 78 countries and regions and 65 organizations worldwide. This has laid a solid foundation for MOTI Mojo to obtain international customer recognition and to participate in bilateral and multilateral scientific research, exchange and cooperation.
The accreditation standards of the China National Accreditation Service for Conformity Assessment (CNAS) are high, the review process is lengthy, the procedures are strict, and the difficulty of passing is great, resulting in few electronic cigarette companies being accredited by CNAS. However, the Rayyan Testing Center was able to successfully pass the CNAS certification, which is closely related to its strong research and development capabilities and quality assurance efforts.
Since its inception, Leiyan Technology has been dedicated to technology research and development and continuous innovation. The company established the "2019 Laboratory" in accordance with the CNAS standards at an early stage, which was officially put into use in 2019. The laboratory has three core capabilities: chemical experiments, physical testing, and reliability testing. Leiyan Technology insists on continuous investment in the production research and development of core materials and exploration of aerosol health basic science. They implement a globally leading product quality management system and have always been the core support of the MOTI MoDi full-line product lifecycle testing and monitoring process.
Tech company Leiyan is reportedly intensifying its development of new products that comply with national standards. Multiple products have already undergone technical evaluations and have achieved a high rate of approval within the industry. Leiyan has stated that it will adhere to its "2FIRSTS" industry values, guided by management regulations, with a focus on product-driven innovation and investment in research and development. The company aims to maintain a leading edge and provide users with quality products to support the technological revolution and high-quality development of the e-cigarette industry.
Statement
This article includes excerpts or republished content sourced from third-party information that is owned by the original media and author. If there is any infringement, please contact us for removal. Any individuals or organizations that wish to repost must contact the author directly, and are not permitted to repost without permission.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
